Remove Drugs Remove Gene Remove Genomics Remove Pharma Companies
article thumbnail

Gene editing: beyond the hype

pharmaphorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space.

article thumbnail

Genomic testing ‘should be offered to all cancer patients in Scotland’

pharmaphorum

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs. The post Genomic testing ‘should be offered to all cancer patients in Scotland’ appeared first on.

Genome 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How epilepsy researchers are moving the needle past anti-seizure treatments

Pharmaceutical Technology

Although recently approved drugs can treat seizures more safely, they do not treat the comorbidities that patients experience. Several biotech companies and researchers are now exploring medical devices and gene therapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome.

Research 264
article thumbnail

New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing

pharmaphorum

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. He said: “These big pharma companies have every type of technology available to them.

article thumbnail

Nine new industry collaborations driving drug discovery forward

Drug Discovery World

Closed Loop Medicine and Pharmanovia TechBio Closed Loop Medicine and pharma company have initiated the OptiZest study and recruited the first patient. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine.

Drugs 52
article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% The modernisation of R&D models could be key to reducing spend on new drugs, a point that Deloitte makes about the need to transform the clinical trials process. the industry experienced in 2021.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. The CDD will sponsor and manage KWF-supported trials. billion ($7.9

Drugs 59